National Cancer Institute (NCI): Sarcoma trials

The registry lists 145 Sarcoma studies with National Cancer Institute (NCI) as lead sponsor. 6 are open to participants now and 56 have results posted.

Phase 1 56Phase 2 85Phase 3 3No phase 18(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal TumorCompletedNCT00087074Phase 2
• Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansCompletedNCT00084630Phase 2
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsCompletedNCT00077454Phase 1
• Perifosine in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00064324Phase 2
• Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00064142Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone SarcomaCompletedNCT00031915Phase 2
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of ChildhoodCompletedNCT00030667Phase 2
• Eligibility Screening for the NIH Intramural Research Program Clinical ProtocolsCompletedNCT00026754
• Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United StatesCompletedNCT00026728
• BMS-275291 in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00024024Phase 1/2
• BMS-247550 in Treating Patients With Advanced Soft Tissue SarcomaTerminatedNCT00022542Phase 2
• A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's SarcomaTerminatedNCT00020683Phase 2
• Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00020449Phase 2
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00020267Phase 1
• Temozolomide and O6-benzylguanine in Treating Children With Solid TumorsCompletedNCT00020150Phase 1
• Liposomal Doxorubicin in Treating Children With Refractory Solid TumorsCompletedNCT00019630Phase 1
• Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV InfectionCompletedNCT00019240Phase 2
• Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00019188Phase 1/2
• Thalidomide in Treating Patients With HIV-Associated Kaposi's SarcomaCompletedNCT00019123Phase 2
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or LymphomasCompletedNCT00012181Phase 1
• Late Effects of Treatment for Sarcomas in ChildrenCompletedNCT00006515
• EMD 121974 in Treating Patients With HIV-Related Kaposi's SarcomaTerminatedNCT00006222Phase 1
• Effects of Potent Antiretroviral Therapy on Kaposi s SarcomaCompletedNCT00006171
• SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue SarcomasCompletedNCT00005862Phase 2
• Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive ChemotherapyCompletedNCT00004853Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue SarcomaCompletedNCT00003778Phase 2
• Chemotherapy in Treating Children With Recurrent or Refractory SarcomasCompletedNCT00003745Phase 2
• Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's SarcomaCompletedNCT00003350Phase 3
• Docetaxel in Treating Children With Recurrent Solid TumorsCompletedNCT00002825Phase 2
• Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal TumorCompletedNCT00002643Phase 2
• Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare DiseasesCompletedNCT00001686
• Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the ExtremityCompletedNCT00001577Phase 1
• A Phase I Study of SU101 in Pediatric Patients With Refractory MalignancyCompletedNCT00001573Phase 1
• A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric SarcomasCompletedNCT00001564Phase 2
• Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated CancersCompletedNCT00001560
• New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and NeuroblastomaCompletedNCT00001335Phase 2
• A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue SarcomaCompletedNCT00001300Phase 3
• Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility AntigensCompletedNCT00001294
• A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal TumorsCompletedNCT00001209Phase 1
• The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue TumorsCompletedNCT00001189Phase 2
• The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the ExtremitiesCompletedNCT00001188Phase 2